These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24738186)

  • 1. [Development of novel therapeutic approaches for Duchenne muscular dystrophy].
    Takeshima Y
    No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186
    [No Abstract]   [Full Text] [Related]  

  • 2. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.
    Takeshima Y; Wada H; Yagi M; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
    Brain Dev; 2001 Dec; 23(8):788-90. PubMed ID: 11720794
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 5. The potential of exon skipping for treatment for Duchenne muscular dystrophy.
    Partridge T
    J Child Neurol; 2010 Sep; 25(9):1165-70. PubMed ID: 20519674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Frontline studies on Duchenne muscular dystrophy treatment].
    Matsuo M
    No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antisense oligos for muscular dystrophy].
    Nagata T; Takeda S
    Rinsho Shinkeigaku; 2010 Nov; 50(11):843. PubMed ID: 21921467
    [No Abstract]   [Full Text] [Related]  

  • 9. [Molecular therapy for duchenne muscular dystrophy].
    Takeshima Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():626-31. PubMed ID: 16416864
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment with antisense oligonucleotides in Duchenne's disease].
    Pascual-Pascual SI
    Rev Neurol; 2012 May; 54 Suppl 3():S31-9. PubMed ID: 22605630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
    Yokota T; Duddy W; Echigoya Y; Kolski H
    Expert Opin Biol Ther; 2012 Sep; 12(9):1141-52. PubMed ID: 22650324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview on DMD exon skipping.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational development of splice-modifying antisense oligomers.
    Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
    Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in therapy for Duchenne muscular dystrophy.
    Fairclough RJ; Bareja A; Davies KE
    Exp Physiol; 2011 Nov; 96(11):1101-13. PubMed ID: 21804140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Mendell JR; Sahenk Z
    Curr Neurol Neurosci Rep; 2013 Mar; 13(3):332. PubMed ID: 23328943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
    Wilton SD; Fletcher S
    Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
    Takeshima Y
    Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.